Product Datasheet

NQO-1 Antibody (A180) - BSA Free NB200-209

Unit Size: 0.1 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 55

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NB200-209

Updated 4/13/2025 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NB200-209



NB200-209

NQO-1 Antibody (A180) - BSA Free


Product Information		
Unit Size	0.1 ml	
Concentration	1.0 mg/ml	
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.	
Clonality	Monoclonal	
Clone	A180	
Preservative	0.02% Sodium Azide	
Isotype	IgG1	
Purity	Protein G purified	
Buffer	PBS	
Target Molecular Weight	31 kDa	
Product Description		
Host	Mouse	
Gene ID	1728	
Gene Symbol	NQO1	
Species	Human, Mouse, Rat, Canine, Primate	
Reactivity Notes	Mouse reactivity reported in scientific literature (PMID: 24475200)	
Specificity/Sensitivity	Does not cross-react with NQO2.	
Immunogen	Full length recombinant NQO1 from human lung [UniProt# P15559]	
Product Application Details		
Applications	Western Blot, Simple Western, Flow Cytometry, Flow (Intracellular), Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Immunoprecipitation	
Recommended Dilutions	Western Blot 1:1000, Simple Western 1:100, Flow Cytometry 1-2 ug/mL, Immunohistochemistry 1:100, Immunocytochemistry/ Immunofluorescence 1:50, Immunoprecipitation 1:1000, Immunohistochemistry-Paraffin 1:100, Immunohistochemistry-Frozen 1:100, Flow (Intracellular)	




Application Notes	In Western blot a band can be seen at approx. 31 kDa representing NQO1. In ICC/IF, cytoplasmic staining was observed in U2OS cells. In IHC-P, staining was observed in the cytoplasm of human breast cancer tisSue. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. Prior to immunostaining paraffin tissues, antigen retrieval with sodium citrate buffer (pH 6.0) is recommended.
	In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. See <u>Simple Western Antibody Database</u> for Simple Western validation: Tested in A431 lysate 0.5 mg/mL, separated by Size, antibody dilution of 1:100, apparent MW was 37 kDa. Separated by Size-Wes, Sally Sue/Peggy Sue. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.


Images

Western Blot: NQO-1 Antibody (A180) [NB200-209] - Antioxidant enzyme synthesis in response to orange oil treatment. Immunoblot analysis demonstrating expression of NQO1 protein at 6, 12 and 24 hrs following 15 min treatment of BEAS-2B cells with the oil preparation or time-matched soy oil control. Representative blots from one of three separate experiments are shown above. Densitometric evaluations of each target protein blot normalized to its corresponding GAPDH for all three experiments are provided below. Bars represent mean +/- SEM. Image collected and cropped by CiteAb from the following publication (https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-12-92), licensed under a CC-BY license.






Immunohistochemistry-Paraffin: NQO-1 Antibody (A180) [NB200-209] - Analysis of NQO1 in human breast cancer using DAB with hematoxylin counterstain.






Page 3 of 13 v.20.1 Updated 4/13/2025











Page 5 of 13 v.20.1 Updated 4/13/2025










Western Blot: NQO-1 Antibody (A180) [NB200-209] - Activation of Nrf2 signaling pathway by FST in RAW 264.7 mouse macrophage-like cells. Cells were treated with FST with or without 100 ng/mL RANKL for 5 days. (A) Total cellular proteins were isolated from cells & the expression levels of Nrf2 & its regulatory proteins were assessed by Western blot analysis. β -actin was used as the internal control. (C) The expression of nuclear & cytosol Nrf2 were determined by Western blotting. Lamin B & β-actin were used as internal controls for the nuclear & cytosolic fractions, respectively. The results shown are representative of three independent experiments. (B,D) Statistical analyses were conducted using analysis of variances between groups. * p < 0.05 & *** p < 0.0001 when compared to control. # p < 0.05 & ### p < 0.0001 when compared to RANKL treatment. RANKL: receptor of activator of nuclear factor kappa-B ligand; FST: fermented sea tangle extract; Nrf2: nuclear factorerythroid 2-related factor 2; p-Nrf2: phosphorylated nuclear factorerythroid 2-related factor 2; HO-1: heme oxygenase-1; NQO-1: NAD(P)H quinone oxidoreductase 1; +: cells treated the reagent; -: cells untreated the reagent. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31357503), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NQO-1 Antibody (A180) [NB200-209] - Nrf2-pathway activation by hybrids: nuclear translocation & targets induction. (A) Nuclear cellular extracts of SH-SY5Y cells were treated for 3 hours with compounds at 5 µM, 500 nM, & 50 nM or with 20, 10, & 5 µM dimethyl fumarate (DMF). Nrf2 protein content in the nucleus was determined by Western blot. Anti-lamin A/C was used as a protein loading control. Results are shown as ratio Nrf2/lamin A/C ± SEM; *p < 0.05, **p < 0.01 & ****p < 0.0001 versus CTR; Dunnett's multiple comparison test (F ratio = 6.797, n≥3). (B–C) RNA from total cellular extracts of SH-SY5Y cells, treated for 24 hours with 5 µM compounds or 20 µM DMF, were analyzed for NQO1 (B) & HO-1 (C) mRNA expression by RT-qPCR. GAPDH was used as housekeeping gene. Results are shown as mean ± SEM; *p < 0.05, **p < 0.01, & ***p < 0.001 versus CTR; Dunnett's multiple comparison test (B, n≥3, F ratio = 10.44; C, n≥3, F ratio = 13.95). (D–E) Cellular extracts of SH-SY5Y cells treated for 24 hours with compounds at 5 μ M or 20 μ M DMF were analyzed for NQO1 (D) & HO-1 (E) protein levels by Western blot. Anti-actin was used as protein loading control. Results are shown as ratio (% of CTR) ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, & ****p < 0.0001 versus CTR; Dunnett's multiple comparison test (D, n \ge 3, F ratio = 5.144; E, n \ge 3, F ratio = 17.26). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32047434), licensed under a CC-BY license. Not internally tested by Novus Biologicals.





Western Blot: NQO-1 Antibody (A180) [NB200-209] - The effects of PI3K/Akt & ER inhibitors on S-(-)equol-induced Nrf2 activation in endothelial cells.(A) EA.hy926 cells or HUVECs transfected w/ ARE-dependent firefly luciferase reporter gene (F) & the renilla firefly luciferase gene (R), & treated w/ 250 nM S-(-)equol in the presence or absence of 10 μ M LY294002 or 100 nM ICI182,780 for 16 h. The potency of induction is expressed as the relative luminescence (R/F) measured using the dual luciferase reporter assay system (mean ± SD, n = 3). *p<0.05 versus w/ control group, #p<0.05 versus w/ S-(-)equol treated group. (B) EA.hy926 cells or HUVECs incubated w/ or w/out 10 μ M LY294002 or 100 nM ICI182,780 for 30 min & then w/ or w/out 10 μ M LY294002 or 100 nM ICI182,780 for 30 min & then w/ or w/out 250 nM S-(-)equol or 500 nM daidzein for 24 h. Whole cell lysates then immunoblotted w/ antibodies against Nrf2, HO-1, NQO1, & β -tubulin. Values are means of three independent experiments w/ standard deviations represented by vertical bars. Mean values significantly different compared w/ controls (*p<0.05). (C) EA.hy926 cells or HUVECs cotransfected w/ the HA-Nrf2 & renilla firefly luciferase expression plasmids treated w/ 250 nM S-(-)equol in the presence or absence of 10 μ M LY294002 or 100 nM ICI182,780 for 16 h, & HA-Nrf2 localization analyzed by confocal microscopy. (D) EA.hy926 cells incubated w/ 250 nM S-(-)equol, 500 nM daidzein w/ or w/out 10 μ M LY294002 or 100 nM ICI182,780 for 16 h, & then immunostained w/ an antibody against Nrf2, & Nrf2 localization analyzed by vertical bars. *p<0.05 versus w/ control group, #p<0.05 versus w/ S-(-)equol treated group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24260155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.	
Western Blot: NQO-1 Antibody (A180) [NB200-209] - S-(-)equol primarily up-regulated Nrf2 protein expression activating ARE-dependent response.(A) Whole EA.hy926 cells lysates of cells treated with 250 nM S-(-)equol, 500 nM daidzein, or 50 μ M tBHQ for 24 h were subjected to immunoblot analysis with anti-Nrf2, anti-HO-1, anti-NQO1, & anti- β -tubulin antibodies. (B) Total HUVECs lysates of cell treated with 250 nM S-(-)equol for 24 h were immunoblotted with anti-Nrf2 & anti- β -tubulin antibodies. (C) EA.hy926 cells were transfected with plasmids containing an HA-tagged Nrf2 open reading frame & the renilla firefly luciferase gene. Medium was changed after 6 hours of incubation. Where indicated, extracts from HA-Nrf2 EA hy.92 cells were additionally probed with anti-HA antibody, anti-Nrf2, anti-HO-1, anti-NQO1 & anti- β -tubulin antibodies. Values are means of three independent experiments with standard deviations represented by vertical bars. Mean values were significantly different compared to controls (*p<0.05). Total RNA was extracted from EA.hy926 cells or HUVECs treated as indicated, & Nrf2 (D), HO-1 (E), & NQO1 (F) mRNA was measured by real-time RT-PCR analysis. The values shown represent the mean \pm SD obtained for three independent experiments (*p<0.05). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24260155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.	HA-Nrf2 plasmid Ion build Ion



Page 8 of 13 v.20.1 Updated 4/13/2025

Page 9 of 13 v.20.1 Updated 4/13/2025

A) Western Blot: NQO-1 Antibody (A180) [NB200-209] - Activation of Nrf2 400 800 FST (µg/mL) 200 signaling pathway by FST in RAW 264.7 mouse macrophage-like cells. RANKL (100 ng/mL) Cells were treated with FST with or without 100 ng/mL RANKL for 5 days. (A) Total cellular proteins were isolated from cells & the expression Nrf2 levels of Nrf2 & its regulatory proteins were assessed by Western blot analysis. β-actin was used as the internal control. (C) The expression of p-Nrf2 nuclear & cytosol Nrf2 were determined by Western blotting. Lamin B & β-actin were used as internal controls for the nuclear & cytosolic HO-1 fractions, respectively. The results shown are representative of three independent experiments. (B,D) Statistical analyses were conducted NQO-1 using analysis of variances between groups. * p < 0.05 & *** p < 0.0001 when compared to control. # p < 0.05 & ### p < 0.0001 when compared β-actin to RANKL treatment. RANKL: receptor of activator of nuclear factor kappa-B ligand; FST: fermented sea tangle extract; Nrf2: nuclear factorerythroid 2-related factor 2; p-Nrf2: phosphorylated nuclear factorerythroid 2-related factor 2; HO-1: heme oxygenase-1; NQO-1: NAD(P)H quinone oxidoreductase 1; +: cells treated the reagent; -: cells untreated the reagent. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31357503), licensed under a CC-BY license. Not internally tested by Novus Biologicals. NQO-1 (A180) was detected in immersion fixed U-2 OS human osteosarcoma cell line using Mouse anti-NQO-1 (A180) Protein G

Purified Monoclonal Antibody conjugated to DyLight 650 (Catalog # NB200-209C) (light blue) at 10 μ g/mL overnight at 4C. Cells were counterstained with DAPI (blue). Cells were imaged using a 100X objective and digitally deconvolved.





Publications

LaPak KM, Saeidi S, Bok I, Wamsley NT et Al. Proximity proteomic analysis of the NRF family reveals the Parkinson's disease protein ZNF746/PARIS as a co-complexed repressor of NRF2 Sci Signal 2023-12-12 [PMID: 38085818]

Liu X, Yan C, Chang C et al. FOXA2 Suppression by TRIM36 Exerts Anti-Tumor Role in Colorectal Cancer Via Inducing NRF2/GPX4-Regulated Ferroptosis Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023-10 -24 [PMID: 37875418]

Details:

1:1000 ICC/IF dilution

Meister ML, Feresin RG Blackberry consumption protects against e-cigarette-induced vascular oxidative stress in mice Food & function 2023-11-08 [PMID: 37937402]

Zarcone G, Lenski M, Martinez T et al. Impact of Electronic Cigarettes, Heated Tobacco Products and Conventional Cigarettes on the Generation of Oxidative Stress and Genetic and Epigenetic Lesions in Human Bronchial Epithelial BEAS-2B Cells Toxics 2023-10-10 [PMID: 37888697] (WB, Human)

Details:

1:1000 WB dilution

Wu D, Sun Q, Wei W et al. Nrf2-mediated protective effect of alpha-lipoic acid on synaptic oxidative damage and inhibition of PKC/ERK/CREB pathway in bisphenol A-exposed HT-22 cells Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2023-10-17 [PMID: 37858839] (Western Blot, Mouse)

Wamsley NT, Wilkerson EM, Guan L et al. Targeted proteomic quantitation of NRF2 signaling and predictive biomarkers in HNSCC Molecular & cellular proteomics : MCP 2023-09-14 [PMID: 37716475] (WB, Human)

Najjar R Raspberry Polyphenols Target Molecular Pathways of Heart Failure Thesis 2023-01-01

Wang X, Wang W, Zhang R et al. Melatonin attenuates high glucose?induced endothelial cell pyroptosis by activating the Nrf2 pathway to inhibit NLRP3 inflammasome activation Molecular medicine reports 2023-03-01 [PMID: 36799176] (WB, Human)

Moore TM, Cheng L, Wolf DM et al. Parkin regulates adiposity by coordinating mitophagy with mitochondrial biogenesis in white adipocytes Nature communications 2022-11-04 [PMID: 36333379] (WB, Mouse)

Meister ML, Najjar RS, Danh JP et al. Berry consumption mitigates the hypertensive effects of a high-fat, highsucrose diet via attenuation of renal and aortic AT1R expression resulting in improved endothelium-derived NO bioavailability The Journal of nutritional biochemistry 2022-11-23 [PMID: 36435288] (WB, Human, Mouse)

Petrillo S, D'Amico J, Nicita F et al. Antioxidant Response in Human X-Linked Adrenoleukodystrophy Fibroblasts Antioxidants 2022-10-28 [PMID: 36358497] (WB, Human)

Li Q, Fadoul G, Ikonomovic M et al. Sulforaphane promotes white matter plasticity and improves long-term neurological outcomes after ischemic stroke via the Nrf2 pathway Free radical biology & medicine 2022-10-13 [PMID: 36244590] (IF/IHC, Mouse)

More publications at http://www.novusbio.com/NB200-209



Procedures

Western Blot Protocol for NQO1 Antibody (NB200-209)

Western Blot Protocol

1. Perform SDS-PAGE on samples to be analyzed, loading 40 ug of total protein per lane.

2. Transfer proteins to membrane according to the instructions provided by the manufacturer of the membrane and transfer apparatus.

3. Stain according to standard Ponceau S procedure (or similar product) to assess transfer success, and mark molecular weight standards where appropriate.

4. Rinse the blot.

5. Block the membrane using standard blocking buffer for at least 1 hour.

6. Wash the membrane in wash buffer three times for 10 minutes each.

7. Dilute primary antibody in blocking buffer and incubate 1 hour at room temperature.

8. Wash the membrane in wash buffer three times for 10 minutes each.

9. Apply the diluted HRP conjugated secondary antibody in blocking buffer (as per manufacturers instructions) and incubate 1 hour at room temperature.

10. Wash the blot in wash buffer three times for 10 minutes each (this step can be repeated as required to reduce background).

11. Apply the detection reagent of choice in accordance with the manufacturers instructions.

Note: Tween-20 can be added to the blocking or antibody dilution buffer at a final concentration of 0.05-0.2%.

Immunohistochemistry-Paraffin Embedded Sections

Antigen Unmasking:

Bring slides to a boil in 10 mM sodium citrate buffer (pH 6.0) then maintain at a sub-boiling temperature for 10 minutes. Cool slides on bench-top for 30 minutes.

Staining:

1. Wash sections in deionized water three times for 5 minutes each.

2. Wash sections in wash buffer for 5 minutes.

3. Block each section with 100-400 ul blocking solution for 1 hour at room temperature.

4. Remove blocking solution and add 100-400 ul diluted primary antibody. Incubate overnight at 4 C.

5. Remove antibody solution and wash sections in wash buffer three times for 5 minutes each.

6. Add 100-400 ul biotinylated diluted secondary antibody. Incubate 30 minutes at room temperature.

7. Remove secondary antibody solution and wash sections three times with wash buffer for 5 minutes each.

8. Add 100-400 ul Streptavidin-HRP reagent to each section and incubate for 30 minutes at room temperature.

9. Wash sections three times in wash buffer for 5 minutes each.

10. Add 100-400 ul DAB substrate to each section and monitor staining closely.

11. As soon as the sections develop, immerse slides in deionized water.

- 12. Counterstain sections in hematoxylin.
- 13. Wash sections in deionized water two times for 5 minutes each.
- 14. Dehydrate sections.
- 15. Mount coverslips.

*The above information is only intended as a guide. The researcher should determine what protocol best meets their needs. Please follow safe laboratory procedures.



Immunohistochemistry-Paraffin Protocol for NQO-1 Antibody (NB200-209)

Immunohistochemistry-Paraffin Embedded Sections

Antigen Unmasking:

Bring slides to a boil in 10 mM sodium citrate buffer (pH 6.0) then maintain at a sub-boiling temperature for 10 minutes. Cool slides on bench-top for 30 minutes (keep slides in the sodium citrate buffer at all times).

Staining:

- 1. Wash sections in deionized water three times for 5 minutes each.
- 2. Wash sections in PBS for 5 minutes.
- 3. Block each section with 100-400 ul blocking solution (1% BSA in PBS) for 1 hour at room temperature.
- 4. Remove blocking solution and add 100-400 ul diluted primary antibody. Incubate overnight at 4 C.
- 5. Remove antibody solution and wash sections in wash buffer three times for 5 minutes each.
- 6. Add 100-400 ul HRP polymer conjugated secondary antibody. Incubate 30 minutes at room temperature.
- 7. Wash sections three times in wash buffer for 5 minutes each.
- 8. Add 100-400 ul DAB substrate to each section and monitor staining closely.
- 9. As soon as the sections develop, immerse slides in deionized water.
- 10. Counterstain sections in hematoxylin.
- 11. Wash sections in deionized water two times for 5 minutes each.
- 12. Dehydrate sections.
- 13. Mount coverslips.





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA Phone: 303.730.1950 Toll Free: 1.888.506.6887 Fax: 303.730.1966 nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402 canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com Technical Support: nb-technical@biotechne.com Orders: nb-customerservice@bio-techne.com General: novus@novusbio.com

Products Related to NB200-209

NBL1-13761	NQO-1 Overexpression Lysate
HAF007	Goat anti-Mouse IgG Secondary Antibody [HRP]
NB720-B	Rabbit anti-Mouse IgG (H+L) Secondary Antibody [Biotin]
NBP1-97005-0.5mg	Mouse IgG1 Isotype Control (MG1)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB200-209

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

